Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Pati

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative is a phase 2/3, randomised interventional study registered as NCT04929041 by National Cancer Institute (NCI), with a registry enrolment figure of 427 participants, started 2022-10-07 and due to reach its primary completion in 2030-12-12. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography; Quality-of-Life Assessment; Radiation Therapy. Conditions listed: Lung Adenocarcinoma; Lung Adenosquamous Carcinoma; Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8. Primary outcome: Progression-free survival (PFS) (Phase II); Overall survival (OS) (Phase III). Lung eligibility wording from the registry: "* Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease)". Sites: United States. No results are recorded here; the registry entry is the source.